Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:6166 |
Name | prostatic urethra urothelial carcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer urethra cancer male urethral cancer prostatic urethral cancer prostatic urethra urothelial carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00794950 | Phase II | Sunitinib | Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma | Completed | USA | 0 |
NCT01688999 | Phase II | Cabozantinib | Cabozantinib for Advanced Urothelial Cancer | Completed | USA | 0 |
NCT03106610 | Phase I | Nivolumab | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | Terminated | USA | 0 |
NCT03549715 | Phase Ib/II | Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Tremelimumab + Vinblastine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO) | Active, not recruiting | FRA | 0 |
NCT04506554 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Nivolumab + Vinblastine | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | Active, not recruiting | USA | 0 |